BioCentury
ARTICLE | Finance

MorphoSys ventures in

Strategic fit of Lanthio's peptides triggers MorphoSys' first venture investment

December 10, 2012 8:00 AM UTC

MorphoSys AG (Xetra:MOR; Pink:MPSYF) is taking a page out of the playbook of Celgene Corp. (NASDAQ:CELG) by making a strategic investment in an early stage biotech.

Last month, MorphoSys participated in the €4.8 million ($6.2 million) series A round for Dutch peptide company Lanthio Pharma B.V. The round was co-led by existing investor BioGeneration Ventures and new investor INKEF Capital. New investor Hanzepoort also participated...